Inserm Transfert Initiative (ITI) was created under the initiative of Inserm, the French National Institute of Health and Medical Research. Inserm is a biomedical and public health research institution with nearly 15,000 researchers, engineers, technicians and post-doctoral students as well as over 300 laboratories. It is the number one academic and clinical research organisation dedicated to human health in Europe.
In 2005, Inserm give Inserm Transfert — the Inserm private subsidiary for scientific tech-transfer — responsibility to establish a new fund, ITI, with the aim of creating a complete ecosystem around academic research institutions and addressing the need to finance early-stage life sciences companies. Together with Inserm Transfert, 3 investment funds - BPI France, Sofinnova Partners and Ventech - supported ITI’s inception.
In 2011, ITI raised €35.5 million from Inserm Transfert, BPI France (through the “Fonds National d’Amorçage”) and 10 pharmaceutical companies, making it one of the largest French life sciences seed investment funds.
Since September 2017, Inserm Transfert Initiative is managed by Sofimac Innovation.
ITI has developed a strong ecosystem of close partners, including:
- Academic institutions: Inserm, CNRS, Pasteur Institute and other members of Aviesan, the French National Alliance for Life Sciences and Health,
- Pharmaceutical and biotech companies,
- Leading venture capital firms.
These strong connections with public and private partners will facilitate finding, seeding and growing our portfolio companies.